Samson Mebrahtu, MD
Neurology · Bay Shore, NYNPI 1528030277
Payments from drug & device makers
Across 158 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$382
- Amgen$291
- Novartis$273
- AstraZeneca$265
- UCB, Inc.$177
- Lundbeck LLC$165
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,140100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $382 |
| Amgen(2 entities) | 14 | $291 |
| Novartis | 19 | $273 |
| AstraZeneca(2 entities) | 14 | $265 |
| UCB, Inc. | 9 | $177 |
| Lundbeck LLC | 12 | $165 |
| Neurelis, Inc. | 6 | $141 |
| Eisai Inc. | 7 | $137 |
| Adamas Pharmaceuticals, Inc. | 7 | $122 |
| Bausch Health US, LLC | 1 | $116 |
| Braemar Manufacturing, LLC | 1 | $108 |
| Argenx US, Inc. | 3 | $79 |
| Neurocrine Biosciences, Inc. | 3 | $78 |
| Acadia Pharmaceuticals Inc | 6 | $73 |
| GRT US Holding, Inc. | 4 | $69 |
| Merz North America, Inc. | 3 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $50 |
| Acorda Therapeutics, Inc | 3 | $39 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Avion Pharmaceuticals | 2 | $35 |
| Merz Pharmaceuticals, LLC | 1 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| W. L. Gore & Associates, Inc. | 1 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| EMD Serono, Inc. | 1 | $28 |
| Pfizer | 1 | $28 |
| GE HealthCare | 2 | $24 |
| CSL Behring | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| SK Life Science, Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Biogen | 1 | $19 |
| Lilly USA, LLC | 1 | $15 |
| Saol Therapeutics Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| Medtronic | 1 | $12 |
| Greenwich Biosciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIGRANAL$116
- Cardiac Monitoring Suite$108
How this compares
$3,140 in reported general payments places this provider in the 55th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 78 | $637,320 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 19 | $486,423 |
| AptiomEslicarbazepine Acetate | 17 | $44,659 |
| ValtocoDiazepam | 12 | $34,787 |
| NeuproRotigotine | 13 | $14,291 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 12 | $5,280 |
| Pyridostigmine Bromide | 31 | $3,302 |
| DilantinPhenytoin Sodium Extended | 17 | $3,279 |
| Topiramate | 43 | $2,323 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 118 | $2,096 |
| Rivastigmine | 18 | $1,753 |
| Ropinirole Hcl | 64 | $1,674 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 30 | $1,615 |
| Mycophenolate Mofetil | 11 | $1,418 |
| Gabapentin | 98 | $1,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $15 | $637,32078 claims |
| Neurelis, Inc.Valtoco | $141 | $34,78712 claims |
| UCB, Inc.Neupro | $177 | $14,29113 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $19 | $4,72042 claims |
| PfizerDilantin | $28 | $3,27917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,623 neurology providers in New York.
Other neurology in Bay Shore
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
- Krupa PandeyAlbany$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.